Page results
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
University College London Hospitals (UCLH) is now administering new COVID-19 treatments for patients at highest risk in the community.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This page provides information for patients who are due to be admitted to hospital for bowel surgery.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
This page is for cancer patients receiving immunotherapy treatment.
-
This information is for patients receiving steroids for immunotherapy toxicity.
File results
-
FOI/2023/0481 - Closure of maternity unit to new admissions 2018/23
-
FOI201769 A&E attendances by patients with mental health related issues
-
FOI/2023/0655 - Customer Relationship Management (CRM) system
-
FOI/2023/0672 - Treatment with dermatology and respiratory medicine
-
FOI/2023/0670 - Treatment with immunomodulatory medications
-
FOI/2023/0665 - Trust pathology services
-
FOI/2023/0662 - NEPTS and patient transport services
-
FOI/2023/0658 - Policies/procedures for Non-emergency patient transport services
-
FOI/2023/0651 - Professional nurse advocate
-
FOI/2023/0648 - Robotic Process Automation (RPA)